



SHL/CFO/BSE/01

Date: 30/05/2016

To,
The Manager,
The Bombay Stock Exchange Ltd.
Dept. of Corporate Service,
PJ Tower, Dalal Street,
Mumbai-40001

Scrip code: 537253 (BSE)

Subject: Quarter 4 and Year ended FY 2016 Investor Release

Dear Sir/Madam,

With reference to the above mentioned subject, Please find enclosed the Quarter 4 and Year ended FY 2016 Investor Release for your reference and record. It is therefore requested to kindly upload the same on BSE's website under Corporate Announcement.

Thanking you,

For Sunil Healthcare Ltd.

Rathi
Pawan Rathi

A circular purple stamp for Sunil Healthcare Limited. The text inside the stamp reads: "Sunil Healthcare Limited", "Vijay Tower, 38E/252-A, Shahpur Jat, Panchsheel Park Comm. Complex", and "New Delhi-110049". There are small stars on either side of the company name.

CFO

CC: Calcutta Stock Exchange Ltd.,
7, Lyons Range
Kolkatta-700001

Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049
T: +91 11 49435555/00 F: +91 11 43850087 e-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com
CIN No. L24302DL1973PLC189662

Q4 FY16 Revenue Growth At 31.0% YoY

FY16 Revenue Growth At 12.4% YoY

Growth witnessed in Capsules Business

May 30th, 2016, New Delhi: Sunil Healthcare Ltd, a leading manufacturer of Empty Hard Gelatin Capsules, have announced it's Audited Financial Results for the Quarter and Year ended 31th March 2016.

Key Financial Highlights:

Rs. Million	Q4 FY16	Q4 FY15	YoY%	FY16	FY15	YoY%
Revenue	228.74	174.67	31.0%	816.24	726.36	12.4%
EBITDA	39.07	33.67	16.0%	156.63	124.79	25.5%
<i>EBITDA Margin</i>	17.1%	19.3%		19.2%	17.2%	
EBIT	27.85	24.96	11.6%	118.44	84.77	39.7%
PAT	12.29	13.01	(5.6%)	52.25	39.80	31.3%
<i>PAT Margin</i>	5.4%	7.4%		6.4%	5.5%	
Cash PAT	23.51	21.72	8.2%	90.45	79.81	13.3%
<i>Cash PAT Margin</i>	10.3%	12.4%		11.1%	11.0%	

Q4 & FY16 - Performance Highlights:

Revenues for Q4 FY16 stood at Rs. 228.74 Mn, a growth of 31.0% YoY while the same was Rs. 816.24 Mn for FY16 a growth of 12.4% YoY. The growth was led by traction witnessed in Capsules division which recorded 16.5% growth YoY in FY16.

EBITDA for Q4 FY16 was at Rs. 39.08 Mn, an increase of 16.0% YoY while the same was Rs. 156.63 Mn for FY16 a growth of 25.5% YoY. EBITDA margin stood at 17.1% and 19.2% for Q4 FY16 and FY16 respectively. There is a Margin expansion of 201 bps FY16. The expansion in margin is attributed to operating leverage witnessed with increase in sales to existing as well as new geographies and customers. Growth in the quarter and the fiscal is mainly attributed to volume growth

Profit After Tax for Q4 FY16 was at Rs. 12.29 mn. FY16 PAT stood at Rs. 52.25 Mn a growth of 31.3% YoY. Q4 FY16 Profitability was impacted due to increase in depreciation and interest cost on account of capitalizing the new capex in the capsules division

Commenting on the results, Mr. D. Gnanasekaran (CEO) said "We have reported a good Quarterly as well as Yearly performance with 16.5% growth in Capsule business. It's been a good period for us and we aim to consolidate and further optimize moving forward. We are focused on increasing our share with Pharmaceutical majors and keeping in line with this we shall continuously embark on increasing our capabilities in the Capsules segment. During the fiscal, we encountered some headwinds in our Export sales owing to currency fluctuations in some of our markets which led to temporary moderation of demand. However, this was adequately covered by our domestic sales which yielded a growth of 36% in FY16. We expect to see a normalization in our export sales in the foreseeable future, which shall enable us to also achieve better realizations.



We remain optimistic on our growth path for the coming fiscal and stand committed in delivering value proposition for all our stakeholders”

About Sunil Healthcare Ltd

Sunil Healthcare Ltd, is the second largest manufacturer of Empty Hard Gelatin Capsules in India. A Gol recognized Star Export House, ~40% of revenues are from exports. With four decades of experience, and a strong brand equity “Sunloc”, the company is a preferred vendor for large pharmaceutical companies.

The company was the pioneer of Double lock and Triple lock technology in India. With a strong focus on R &D, the company is constantly innovating its product line to cater to the industry requirements.

For more information, please visit the company website www.sunilhealthcare.com

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For Further Details, Please Contact

Company :

Sunil Healthcare Ltd.
CIN - L24302DL1973PLC189662
Mr. Pawan Rathi, Chief Financial Officer

cfo@sunilhealthcare.com
www.sunilhealthcare.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Mr. Shogun Jain / Ms. Sanjita Ghosh
+91 7738377756 / +91 7738359389
ishogun@sgapl.net / gsanjita@sgapl.net
www.sgapl.net

